OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
181357

Polylite Taiwan Co Ltd

Medical Equipment, Supplies & DistributionVerified

Polylite Taiwan's capital structure shows a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidity is rated as medium, with a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company's cash and equivalents amount to TWD 106,032,000, but this is offset by long-term debt of TWD 217,528,000, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics are weak, with a return on equity (ROE) of -7% and a return on assets (ROA) of -5.14%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating cash flow of TWD 46,809,000 is positive, but the free cash flow is negative at TWD -13,314,000, reflecting capital expenditure outflows of TWD -10,275,000. These metrics fall below the industry median for medical equipment firms, which typically exhibit positive ROE and ROA. The company's revenue is concentrated in the domestic market and overseas markets, with no disclosed segment breakdown. This lack of segment data limits visibility into geographic exposure and product-specific performance. The absence of detailed revenue concentration data makes it difficult to assess the risk of overreliance on any single market or product line. Growth trajectory is uncertain, with no forward-looking revenue guidance provided in the input data. Historical financials show a revenue of TWD 304,320,000, but the company reported a net loss of TWD -47,935,000. The lack of positive earnings and the negative gross profit of TWD -52,322,000 suggest operational challenges. Without clear evidence of margin improvement or cost control, the company's ability to sustain or grow revenue is questionable. Risk factors include medium liquidity risk and a negative net cash position after debt. The company's dilution risk is rated as low, with no near-term pressure from share issuance or convertible instruments. However, the negative net income and operating income raise concerns about the company's ability to service debt and maintain operations without external financing. Recent events include the latest financial filing (HA-latest), which discloses the company's current financial position. No recent earnings call transcripts or material events are included in the input data, limiting insight into management's strategic direction or operational updates.

30-day price · 1813-1.25 (-9.3%)
Low$12.00High$13.65Close$12.15As of22 May, 00:00 UTC
Profile
CompanyPolylite Taiwan Co Ltd
Ticker1813.TWO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Polylite Taiwan Co., Ltd. is a Taiwan-based company engaged in the research, development, manufacture, and distribution of optical lenses, including vision correction, polarized, and anti-blue lenses, primarily for the healthcare sector.

Classification. Polylite Taiwan is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Polylite Taiwan's capital structure shows a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidity is rated as medium, with a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company's cash and equivalents amount to TWD 106,032,000, but this is offset by long-term debt of TWD 217,528,000, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics are weak, with a return on equity (ROE) of -7% and a return on assets (ROA) of -5.14%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating cash flow of TWD 46,809,000 is positive, but the free cash flow is negative at TWD -13,314,000, reflecting capital expenditure outflows of TWD -10,275,000. These metrics fall below the industry median for medical equipment firms, which typically exhibit positive ROE and ROA. The company's revenue is concentrated in the domestic market and overseas markets, with no disclosed segment breakdown. This lack of segment data limits visibility into geographic exposure and product-specific performance. The absence of detailed revenue concentration data makes it difficult to assess the risk of overreliance on any single market or product line. Growth trajectory is uncertain, with no forward-looking revenue guidance provided in the input data. Historical financials show a revenue of TWD 304,320,000, but the company reported a net loss of TWD -47,935,000. The lack of positive earnings and the negative gross profit of TWD -52,322,000 suggest operational challenges. Without clear evidence of margin improvement or cost control, the company's ability to sustain or grow revenue is questionable. Risk factors include medium liquidity risk and a negative net cash position after debt. The company's dilution risk is rated as low, with no near-term pressure from share issuance or convertible instruments. However, the negative net income and operating income raise concerns about the company's ability to service debt and maintain operations without external financing. Recent events include the latest financial filing (HA-latest), which discloses the company's current financial position. No recent earnings call transcripts or material events are included in the input data, limiting insight into management's strategic direction or operational updates.
Key takeaways
  • Polylite Taiwan is operating at a loss with negative returns on equity and assets.
  • The company's liquidity is constrained, with a current ratio of 1.13 and a negative net cash position after debt.
  • Revenue concentration data is not disclosed, limiting visibility into geographic and product-specific risks.
  • Growth prospects are unclear due to the absence of forward-looking guidance and negative operating performance.
  • Dilution risk is low, but the company may require external financing to sustain operations.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$304.3M
Gross profit-$52.3M
Operating income-$127.3M
Net income-$47.9M
R&D
SG&A
D&A
SBC
Operating cash flow$46.8M
CapEx-$10.3M
Free cash flow-$13.3M
Total assets$931.8M
Total liabilities$247.2M
Total equity$684.5M
Cash & equivalents$106.0M
Long-term debt$217.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$684.5M
Net cash-$111.5M
Current ratio1.1
Debt/Equity0.3
ROA-5.1%
ROE-7.0%
Cash conversion-98.0%
CapEx/Revenue-3.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric1813Activity
Op margin-41.8%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-15.8%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin-17.2%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.4%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity32.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 06:49 UTC#cbcc2667
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 06:51 UTCJob: 751c4f97